Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-17

Clinical Trial Update: TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update for ruxolitinib cream in adolescents and adults with atopic dermatitis; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ruxolitinib Cream (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-17